Lykke Hinsch Gylvin, Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim at Boehringer Ingelheim, shared on LinkedIn:
“Patients need new treatment options sooner.
Hence, accelerated clinical research and evidence generation is a necessity for therapeutic innovation to reach them in the most efficient manner.
As the development of new medicines becomes increasingly complex, we have a responsibility to deliver on this need.
The value of technology lies in enabling data-backed scientific decisions, that translate into a more meaningful and patient-centric clinical trial design and delivery.
That’s why Boehringer Ingelheim’s collaboration with Microsoft, combining our scientific and clinical expertise with Microsoft’s data and AI capabilities, gains significance.
Together, we are exploring how technology – including simulation models such as patient digital twins can enable faster and smarter clinical development, enhancing patient-centric clinical development without compromising rigor.
Our responsibility is to bring scientific ambition and accountability together, keeping patients’ needs central to the questions we ask and the evidence we generate. Ultimately, the measure of progress is what changes in their lives.
Innovative science. A strong data foundation. Simulation on disease progression. All of them deliver better outcomes for patients.”
Other articles about Boehringer Ingelheim and Microsoft on OncoDaily.